The Possibility of Epidermal Growth Factor Receptor Inhibition in Anal Cancer
Authors:
I. Richter 1; J. Dvořák 2
; T. Jirásek 3; J. Bartoš 1
Authors place of work:
Onkologické oddělení, Krajská nemocnice Liberec, a. s.
1; Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
2; Oddělení patologie, Krajská nemocnice Liberec, a. s.
3
Published in the journal:
Klin Onkol 2015; 28(4): 260-264
Category:
Review
doi:
https://doi.org/10.14735/amko2015260
Summary
Anal cancer is a relatively rare tumour. In local and locally advanced disease, concomitant chemoradiation based on mitomycin C and 5-fluorouracil, remains golden standard of treatment. However, this treatment is associated with significant morbidity. With the developing of molecular biology, new treatment strategies can be investigated. Epidermal growth factor receptor (EGFR) expression in anal cancer is observed in 55–100% of cases. Some studies demonstrated that KRAS mutations, mechanism marker of resistance to antiEGFR therapy, are rare in anal cancer. This paper presents current view on the possibilities of antiEGFR therapy in locally advanced and metastatic anal cancer.
Key words:
anal cancer – chemoradiotherapy – monoclonal antibodies – epidermal growth factor receptor
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
29. 3. 2015
Accepted:
29. 4. 2015
Zdroje
1. Šlampa P, Vošmik M, Přibylová O et al. Zhoubné nádory anu. In: Šlampa P, Petera J et al (eds). Radiační onkologie. 1. vyd. Praha: Galén 2007: 145– 152.
2. Daling JR, Madeleine MM, Johnson LG et al. Human papillomavirus, smoking, and sexual pracftices in the etiology of anal cancer. Cancer 2004; 101(2): 270– 280.
3. Kocáková I, Kocák I, Soumarová R. Chemoradioterapie nádoru anu. In: Šlampa P, Soumarová R, Kocáková I et al (eds). Konkomitantní chemoradioterapie solidních nádorů. Praha: Galén 2005: 55– 62.
4. Ryan DP, Compton CC, Mayer RJ. Carcinoma of tha anal canal. N Eng J Med 2000; 342(16): 792– 800.
5. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of tha anal canal: a preliminary report. Dis Colon Rectum 1974; 17(3): 354– 356.
6. Cummings BJ, Keane TJ, O’Sullivan B et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5- fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991; 21(5): 1115– 1125.
7. UK Coordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. Lancet 1996; 348(9034): 1049– 1054.
8. Bartelink H, Roelofsen F, Eschwenge F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of phase III randomized trial of the EORTC and Gastrointestinal Coopoerative Groups. J Clin Oncol 1997; 15(5): 2040– 2049.
9. Northover J, Glynne‑ Jones R, Sebag‑ Montefiore D et al. Chemoradiation for the treatment of epidermoid anal cancer: 13‑year follow up of the first randomized UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102(7): 1123– 1128. doi: 10.1038/ sj.bjc.6605605.
10. Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of tha anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14(9): 2527– 2539.
11. Gunderson LL, Winter KA, Ajanu JA et al. Long‑term update of US GI intergroup RTOG 98– 11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/ cisplatine. J Clin Oncol 2012; 30(35): 4344– 4351. doi: 10.1200/ JCO.2012.43.8085.
12. James RD, Glynne‑ Jones R, Meadows HM et al. Mitomycin or cisplatine chemoradiation with or without maintance chemotherapy for treatment of squamous‑ cell carcinoma of the anus (ACT II): a randomized, phase 3,open‑ label, 2 × 2 factorial trial. Lancet 2013; 14(6): 516– 524. doi: 10.1016/ S1470‑ 2045(13)70086‑ X.
13. Cassidy J, Clarke S, Diaz‑ Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatine compared with fluorouracil/ folinic acid plus oxaliplatine as first‑line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26(12): 2006– 2012. doi: 10.1200/ JCO.2007.14.9898.
14. Fuschs CS, Marshall J, Mitchell E et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first‑line treatment of metastatic colorectal cancer: results from BICC‑ C Study. J Clin Oncol 2007; 25(30): 4779– 4789.
15. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatine compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29(11): 1465– 1471. doi: 10.1200/ JCO.2010.33.6297.
16. Hofheinz RD, Wenz F, Post S et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, non‑inferiority, phase 3 trial. Lancet Oncol 2012; 13(6): 579– 588. doi: 10.1016/ S1470‑ 2045(12)70116‑ X.
17. Meulendijks D, Dewit L, Tomasoa NB et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014; 111(9): 1726– 1733. doi: 10.1038/ bjc.2014.467.
18. Goodman K, Rothstein D, Lajhem C et al. Capecitabine plus mitomycin in patients udergoing definitive chemoradiation for anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2014; 90 (Suppl 1): S32– S33.
19. Kazda T, Syptáková B, Šlampa P et al. Zhoubná nádory anu. In: Šlampa P et al (eds). Radiační onkologie v praxi. 3. vyd. Brno: Masarykův onkologický ústav 2011: 78– 85.
20. Menkarios C, Azria D, Laliberte B et al. Optimal organ – sparing intensity modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional IMRT plans. Radiat Oncol 2007; 2: 41.
21. Kachnic LA, Winter K, Myerson RJ et al. RTOG 0529: a phase II evaluation of dose‑painted intensity modulated radiation therapy in combination with 5- fluorouracil and mitomycin C for the reduction of acute morbidity in carcinoma of the anal canal. Int Radiat Oncol Biol Phys 2013; 86(1): 27– 33. doi: 10.1016/ j.ijrobp.2012.09.023.
22. Schiller DE, Cummings BJ, Rai S et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007; 14(10): 2780– 2789.
23. Mullen JT, Rodriguez‑ Bigaz MA, Chang GJ et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 2007; 14(2): 478– 483.
24. Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie 2006; 29(1– 2): 5– 6.
25. Sirák I, Hatlová J, Petera J et al. Receptor pro epidermální růstový faktor a jeho úloha v radioterapii. Klin Okol 2008; 21(6): 338– 347.
26. Willett CG, Duda DG, Czito BG et al. Targeted therapy in rectal cancer. Oncology 2007; 21(9): 1055– 1065.
27. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanism and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl 4): S3– S8.
28. Uberall I, Kolar Z, Trojec R et al. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 2008; 84(2): 79– 89. doi: 10.1016/ j.yexmp.2007.12.002.
29. Akimoto T, Hunter NR, Buchmiller L et al. Inverse relationship between epidermal growth factor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5(10): 2884– 2890.
30. Liang K, Ang KK, Milas L et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Biol Phys 2003; 57(1): 246– 254.
31. Verbeek BS, Andriaansen‑ Slot SS, Vroom TM et al. Overexpression of EGFR and c‑ erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425(1): 145– 150.
32. Withers HR, Taylor JM, Maciejewski B et al. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988; 27(2): 131– 146.
33. Baumann M, Petersen C, Eichler W et al. Mechanism of repopulation in experimental squamos cell carcinoma. In: Kogelnik HD, Lukas P, Sedlmayer F (eds). Progress in radiation‑ oncology. Vol. 7. Bologna: Monduzzi 2002: 417– 422.
34. Begg AC. Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol 1994; 65(1): 103– 108.
35. Fowler JF. Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment‑ continually rapid proliferation inmasked. Radiother Oncol 1991; 22(3): 156– 158.
36. Schmitdt‑ Ullrich RK, Contessa JN, Dent P et al. Molecular mechanism of radiation‑induced accelerated repopulation. Radiat Oncol Investig 1999; 7(6): 321– 330.
37. Alvarez G, Perry A, Tan BR et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of tha anal canal is independent of gene amplification. Mod Pathol 2006; 19(7): 942– 949.
38. Le LH, Chetty R, Moore MJ. Epidermal growth factor receptro expression in anal carcinoma. Am J Clin Pathol 2005; 124(1): 20– 23.
39. Van Damme N, Deron P, Van Roy N et al. Epidermal growth factor receptro and KRAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010; 10: 189. doi: 10.1186/ 1471‑ 2407‑ 10‑ 189.
40. Walker F, Abramowitz L, Benabderrahmane D et al. Growth factor receptro expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodefiuency virus. Hum Pathol 2009; 40(11): 1517– 1527. doi: 10.1016/ j.humpath.2009.05.010.
41. Zampino MG, Magni E, Sonzogni A et al. KRAS status in squamous cell anal carcinoma (SCC): it’s time for target‑ oriented treatment? Cancer Chemother Pharmacol 2009; 65(1): 197– 199. doi: 10.1007/ s00280‑ 009‑ 1117‑ 3.
42. Van Damme N, Deron P, Van Roy N et al. Epidermal growth factor receptor and KRAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010; 10: 189. doi: 10.1186/ 1471‑ 2407‑ 10‑ 189.
43. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non‑small‑cell lung cancer. N Engl J Med 2005; 353(2): 123– 132.
44. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotekan in irinotekan‑ refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337– 345.
45. Van Cutsem E, Kohne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorine as fist‑line treatment for metastatic colorectal cancer: update analysis of overall survival according to tumor KRAS and BRAF station status. J Clin Oncol 2011; 29(15): 2011– 2019. doi: 10.1200/ JCO.2010.33.5091.
46. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first‑line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 663– 671. doi: 10.1200/ JCO.2008.20.8397.
47. Maugham TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatine‑based first‑line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet 2011; 377(9783): 2013– 2114. doi: 10.1016/ S0140‑ 6736(11)60613‑ 2.
48. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, luecovorine, and oxaliplatine (Nordic FLOX) versus FLOX alone in first‑line treatment of metstatic colorectal cancer: the NORDIC‑ VII study. J Clin Oncol 2012; 30(15): 1755– 1762. doi: 10.1200/ JCO.2011.38.0915.
49. Van Cutsem E, Peeters M, Siena S et al. Open.label phase III trial of panitumumab plus bets supportive care compared with best supportive care alone in patiens with chemotherapy‑ refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658– 1664.
50. Oliner KS, Douillard JY, Siena S et al. Analysis of KRAS/ NRAS and BRAF station in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first‑line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31 (Suppl): abstr. 3511.
51. Paliga A, Onerheim R, Gologan A et al. EGFR and KRAS gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 2012; 107(11): 1864– 1868. doi: 10.1038/ bjc.2012.479.
52. Serup‑ Hansen E, Linnemann D, Hogdal E et al. KRAS and BRAF mutation in anal carcinoma. APMIS 2015; 123(1): 53– 59. doi: 10.1111/ apm.12306.
53. Chang SE, Bhatia P, Johnson NW et al. Ras mutation in United Kingdom examples of oral malignances are infrequent. Int J Cancer 1991; 48(3): 409– 412.
54. Wang WY, Chein YC, Wong YK et al. Effects of KRAS status mutation and polymorphismus on the risk and prognosis of oral squamous cell carcinoma. Head Neck 2012; 34(5): 663– 666. doi: 10.1002/ hed.21792.
55. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamos‑ cell carcinoma of head and neck. N Engl J Med 2006; 354(6): 567– 578.
56. Vermorekn JB, Mesia R, Rivera F et al. Platinum‑based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116– 1127. doi: 10.1056/ NEJMoa0802656.
57. Lukan N, Strobel P, Willer A et al. Cetuximab‑based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009; 77(5): 293– 299. doi: 10.1159/ 000259615.
58. Garg M, Lee JY, Kachnic LA et al. Phase II trials of cetuximab (CX) plus cisplatine (CDDP), 5- fluorouracil (5- FU) and radiation (RT) in imonocompetent (ECOG 3205) and HIV‑ positive (AMC045) patients with squamous cell carcinoma of tha anal canal (SCAC): safety and preliminary efficacy results (abstract). ASCO Meeting Anstracts 2012; 30: 4030.
59. Deutsch E, Lemanski C, Pignon JP et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013; 24(11): 2834– 2838. doi: 10.1093/ annonc/ mdt368.
60. Olivatto LO, Viera FM, Pereira BV et al. Phase I study of cetuximab in combination with 5- fluorouracil, cisplatine, and radiotherapy in patients with locally advanced anal carcinoma. Cancer 2013; 119(16): 2973– 2980. doi: 10.1002/ cncr.28045.
61. Saif MW, Kontny E, Syrigos KN et al. The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. J Oncol 2011; 2011: 125467. doi: 10.1155/ 2011/ 125467.
62. Richter I, Dvořák J, Blüml A et al. Vliv předoperační chemoradioterapie na změnu exprese receptoru pro epidermální růstový faktor u pacientů léčených předoperační chemoradioterapií pro lokálně pokročilý karcinom rekta. Klin Onkol 2014; 27(5): 361– 366. doi: 10.14735/amko2014361.
63. Mishani E, Abourbeh G. Cancer molecular imaging: radionuclide‑based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007; 7(18): 1755– 1772.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2015 Číslo 4
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Extraoseus Ewing‘s Sarcoma, Primary Affection of Uterine Cervix – Case Report
- Embryonal Tumors with Multilayer Rosettes – Rare Central Nervous System Tumors in Infants
- Potential of Cell‑free Circulating DNA in Diagnosis of Cancer
- Estimated Glomerular Filtration Rate in Oncology Patients before Cisplatin Chemotherapy